Association between Gut Microbiota and SARS-CoV-2 Infection and Vaccine Immunogenicity

• Published in: Microorganisms (Basel) 2023-02, Vol.11 (2), p.452
• Main Authors: Ng, Ho Yu, Leung, Wai K, Cheung, Ka Shing
• Format: Article
• Language: English
• Subjects: Clinical outcomes; Coronaviruses; COVID-19; COVID-19 vaccine; COVID-19 vaccines; Cross-sectional studies; Cytokine storm; Dysbacteriosis; Fatty acids; Flagellin; gut dysbiosis; gut microbiota; Health aspects; Human subjects; Immune response; Immune system; Immunogenicity; Immunomodulation; Infections; Intestinal microflora; Lipopolysaccharides; Metabolites; Microbiota; Microbiota (Symbiotic organisms); Pandemics; Patients; Peptidoglycans; Physiological aspects; Public health; Review; Rotavirus; Severe acute respiratory syndrome coronavirus 2; Signs and symptoms; vaccine immunogenicity; Vaccines; Viral diseases
• ISSN: 2076-2607; 2076-2607
• DOI: 10.3390/microorganisms11020452

Gut microbiota is increasingly recognized to play a pivotal role in various human physiological functions and diseases. Amidst the COVID-19 pandemic, research has suggested that dysbiosis of the gut microbiota is also involved in the development and severity of COVID-19 symptoms by regulating SARS-CoV-2 entry and modulating inflammation. Previous studies have also suggested that gut microbiota and their metabolites could have immunomodulatory effects on vaccine immunogenicity, including influenza vaccines and oral rotavirus vaccines. In light of these observations, it is possible that gut microbiota plays a role in influencing the immune responses to COVID-19 vaccinations via similar mechanisms including effects of lipopolysaccharides, flagellin, peptidoglycan, and short-chain fatty acids. In this review, we give an overview of the current understanding on the role of the gut microbiota in COVID-19 manifestations and vaccine immunogenicity. We then discuss the limitations of currently published studies on the associations between gut microbiota and COVID-19 vaccine outcomes. Future research directions shall be focused on the development of microbiota-based interventions on improving immune response to SARS-CoV-2 infection and vaccinations.